Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immatics (IMTX)
NASDAQ:IMTX
Immatics (IMTX) Stock Price & Analysis
246 Followers
IMTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.15 - $13.77
Previous Close$12.52
Volume177.23K
Average Volume (3M)503.65K
Market Cap
$1.29B
Enterprise Value$843.09M
Total Cash (Recent Filing)€425.89M
Total Debt (Recent Filing)€15.40M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 06, 2024EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding84,657,789
10 Day Avg. Volume527,307
30 Day Avg. Volume503,651
Standard Deviation0.15
R-Squared0.11
Alpha-0.00118
Financial Highlights & Ratios
Price to Book (P/B)4.68
Price to Sales (P/S)19.39
Price to Cash Flow (P/CF)3.30
P/FCF Ratio3.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.00Price Target Upside43.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Immatics News
PremiumCompany Announcements
Immatics N.V. AGM Concludes Successfully
PremiumCompany Announcements
Immatics N.V. Schedules 2024 Annual Meeting
PremiumCompany Announcements
Immatics N.V. Q1 Financials Show Net Loss Shrinkage
PremiumCompany Announcements
Immatics N.V. Showcases Clinical Strides and Fiscal HealthBulls Say, Bears Say
Bulls Say
Clinical DataThe treatment of 30 patients with GEN1 led to a 55% confirmed overall response rate with a median duration of response of 13.5 months.
Pipeline ProgressThe updated IMA203 data showed a confirmed overall response rate increase to 55% from 50%, supporting plans to begin a registration-directed Phase II/III study in melanoma.
Safety ProfileTreatment with GEN1 has maintained a favorable safety profile with mostly mild to moderate side effects and no Grade 5 adverse events.
Bears Say
Clinical TrialsTwo Grade 5 events were disclosed, one each for IMA401 and IMA203CD8.
PartnershipsIts partnership with Genmab was terminated.
Stock PerformanceIMTX shares have underperformed since the last update.
---
Ownership Overview
0.00%
Insiders
12.56% Mutual Funds
51.18% Other Institutional Investors
36.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMTX FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $7.15 and its highest was $13.77 in the past 12 months.
What is Immatics’s market cap?
Currently, no data Available
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is Aug 06, 2024 which is in 16 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on May 14, 2024. The company reported -$0.044 earnings per share for the quarter, beating the consensus estimate of -$0.222 by $0.179.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -$0.31.
How many shares outstanding does Immatics have?
Immatics has 103,053,444 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of -$0.044 in its last earnings report, beating expectations of -$0.222. Following the earnings report the stock price went up 5.455%.
Which hedge fund is a major shareholder of Immatics?
Among the largest hedge funds holding Immatics’s share is Baker Bros Advisors LP. It holds Immatics’s shares valued at 68M.
---
Immatics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (43.77% Upside)
$18.00 (43.77% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 16.2%
Last 30 Days ▲ 16.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.04%
12-Months-Change
Fundamentals
Return on Equity
-26.77%
Trailing 12-Months
Asset Growth
71.54%
Trailing 12-Months
Company Description
Immatics
Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.
---
IMTX Stock 12 Month Forecast
Average Price Target
$18.00
▲(43.77% Upside)
Technical Analysis
Best Analysts Covering IMTX
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
+1.18%
reiterated a buy rating 2 months ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of +1.18% per trade.
---